Northern Trust
MRKR icon

Northern Trust’s Marker Therapeutics MRKR Stock Holding History

Northern Trust’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.8K Hold
26,009
– – ﹤0.01% 4294
2025
Q4 		$38.8K Buy
26,009
+15,152
+140% +$17.2K ﹤0.01% 4326
2025
Q3 		$9.69K Hold
10,857
– – ﹤0.01% 4407
2025
Q2 		$16.6K Hold
10,857
– – ﹤0.01% 4351
2025
Q1 		$13.4K Sell
10,857
-43,299
-80% -$79.3K ﹤0.01% 4372
2024
Q4 		$168K Buy
54,156
+21,703
+67% +$76.9K ﹤0.01% 4037
2024
Q3 		$91.5K Sell
32,453
-928
-3% -$3.67K ﹤0.01% 4079
2024
Q2 		$181K Sell
33,381
-1,442
-4% -$6.13K ﹤0.01% 3894
2024
Q1 		$150K Sell
34,823
-3,888
-10% -$17K ﹤0.01% 3975
2023
Q4 		$213K Buy
38,711
+27,830
+256% +$94.3K ﹤0.01% 3878
2023
Q3 		$49.4K Hold
10,881
– – ﹤0.01% 4171
2023
Q2 		$33.7K Hold
10,881
– – ﹤0.01% 4305
2023
Q1 		$7.73K Sell
10,881
-2
-0% -$5 ﹤0.01% 4543
2022
Q4 		$28.9K Hold
10,883
– – ﹤0.01% 4404
2022
Q3 		$40K Hold
10,883
– – ﹤0.01% 4384
2022
Q2 		$36K Hold
10,883
– – ﹤0.01% 4500
2022
Q1 		$48K Hold
10,883
– – ﹤0.01% 4542
2021
Q4 		$103K Hold
10,883
– – ﹤0.01% 4412
2021
Q3 		$184K Sell
10,883
-586
-5% -$12K ﹤0.01% 4215
2021
Q2 		$320K Sell
11,469
-22,037
-66% -$580K ﹤0.01% 3903
2021
Q1 		$750K Sell
33,506
-1,392
-4% -$31.8K ﹤0.01% 3689
2020
Q4 		$506K Buy
34,898
+725
+2% +$11.3K ﹤0.01% 3724
2020
Q3 		$513K Sell
34,173
-2,816
-8% -$51.4K ﹤0.01% 3599
2020
Q2 		$766K Buy
36,989
+2,967
+9% +$64.9K ﹤0.01% 3439
2020
Q1 		$647K Buy
34,022
+1,097
+3% +$27.9K ﹤0.01% 3383
2019
Q4 		$948K Buy
32,925
+86
+0.3% +$3.13K ﹤0.01% 3416
2019
Q3 		$1.68M Buy
32,839
+20,517
+167% +$1.21M ﹤0.01% 3197
2019
Q2 		$976K Buy
12,322
+6,845
+125% +$407K ﹤0.01% 3367
2019
Q1 		$361K Sell
5,477
-95
-2% -$5.55K ﹤0.01% 3617
2018
Q4 		$309K Buy
5,572
+3,952
+244% +$288K ﹤0.01% 3665
2018
Q3 		$147K Sell
1,620
-463
-22% -$39.7K ﹤0.01% 3938
2018
Q2 		$197K Buy
+2,083
New +$106K ﹤0.01% 3860

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Northern Trust's MRKR Position: Q1 2026 in Review

Northern Trust held its Marker Therapeutics (MRKR) position steady in Q1 2026 at 26,009 shares worth $33.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4294.

Northern Trust first reported a position in MRKR in Q2 2018 and has held it in 32 quarters since. The position peaked at $1.68M in Q3 2019. 35 funds tracked by Wall St. Rank hold MRKR as of Q1 2026.

  • Northern Trust held 26,009 shares of Marker Therapeutics worth $33.8K as of Q1 2026.
  • Northern Trust left its Marker Therapeutics share count unchanged in Q1 2026.
  • Marker Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4294 holding.
  • Northern Trust first reported a position in Marker Therapeutics in Q2 2018 and has held it in 32 quarters since.
  • Northern Trust's Marker Therapeutics position peaked at $1.68M in Q3 2019.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.